These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 31766908)

  • 41. Randomized, controlled trial of lasmiditan over four migraine attacks: Findings from the CENTURION study.
    Ashina M; Reuter U; Smith T; Krikke-Workel J; Klise SR; Bragg S; Doty EG; Dowsett SA; Lin Q; Krege JH
    Cephalalgia; 2021 Mar; 41(3):294-304. PubMed ID: 33541117
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Characterization of Dizziness After Lasmiditan Usage: Findings From the SAMURAI and SPARTAN Acute Migraine Treatment Randomized Trials.
    Tepper SJ; Krege JH; Lombard L; Asafu-Adjei JK; Dowsett SA; Raskin J; Buchanan AS; Friedman DI
    Headache; 2019 Jul; 59(7):1052-1062. PubMed ID: 31152441
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effects of Lasmiditan on Cardiovascular Parameters and Pharmacokinetics in Healthy Subjects Receiving Oral Doses of Propranolol.
    Tsai M; Case M; Ardayfio P; Hochstetler H; Wilbraham D
    Clin Pharmacol Drug Dev; 2020 Jul; 9(5):629-638. PubMed ID: 31950732
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effects of lasmiditan on simulated driving performance: Results of two randomized, blinded, crossover studies with placebo and active controls.
    Pearlman EM; Wilbraham D; Dennehy EB; Berg PH; Tsai M; Doty EG; Kay GG
    Hum Psychopharmacol; 2020 Sep; 35(5):e2732. PubMed ID: 32449213
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Abuse Potential of Lasmiditan: A Phase 1 Randomized, Placebo- and Alprazolam-Controlled Crossover Study.
    Wilbraham D; Berg PH; Tsai M; Liffick E; Loo LS; Doty EG; Sellers E
    J Clin Pharmacol; 2020 Apr; 60(4):495-504. PubMed ID: 31745991
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Lasmiditan abortive therapy for episodic migraine in Phase II/III randomized clinical trials: A meta-analysis.
    Ahsan M; Mallick AK
    Indian J Pharmacol; 2022; 54(6):397-406. PubMed ID: 36722551
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Issues Impacting Adverse Event Frequency and Severity: Differences Between Randomized Phase 2 and Phase 3 Clinical Trials for Lasmiditan.
    Kudrow D; Krege JH; Hundemer HP; Berg PH; Khanna R; Ossipov MH; Pozo-Rosich P
    Headache; 2020 Mar; 60(3):576-588. PubMed ID: 31943195
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Acute treatment of migraine with the selective 5-HT1F receptor agonist lasmiditan--a randomised proof-of-concept trial.
    Ferrari MD; Färkkilä M; Reuter U; Pilgrim A; Davis C; Krauss M; Diener HC;
    Cephalalgia; 2010 Oct; 30(10):1170-8. PubMed ID: 20855362
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Trajectory of migraine-related disability following long-term treatment with lasmiditan: results of the GLADIATOR study.
    Lipton RB; Lombard L; Ruff DD; Krege JH; Loo LS; Buchanan A; Melby TE; Buse DC
    J Headache Pain; 2020 Feb; 21(1):20. PubMed ID: 32093628
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Lasmiditan for the acute treatment of migraine.
    Tepper D
    Headache; 2020 Jun; 60(6):1225-1226. PubMed ID: 32474924
    [No Abstract]   [Full Text] [Related]  

  • 51. Lasmiditan efficacy in the acute treatment of migraine was independent of prior response to triptans: Findings from the CENTURION study.
    Reuter U; Krege JH; Lombard L; Gomez Valderas E; Krikke-Workel J; Dell-Agnello G; Dowsett SA; Buse DC
    Cephalalgia; 2022 Jan; 42(1):20-30. PubMed ID: 34644189
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Novel Therapies in Acute Migraine Management: Small-Molecule Calcitonin Gene-Receptor Antagonists and Serotonin 1F Receptor Agonist.
    Joyner KR; Morgan KW
    Ann Pharmacother; 2021 Jun; 55(6):745-759. PubMed ID: 32993366
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Lasmiditan is an effective acute treatment for migraine: A phase 3 randomized study.
    Kuca B; Silberstein SD; Wietecha L; Berg PH; Dozier G; Lipton RB;
    Neurology; 2018 Dec; 91(24):e2222-e2232. PubMed ID: 30446595
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Lasmiditan for the acute treatment of migraine: Subgroup analyses by prior response to triptans.
    Knievel K; Buchanan AS; Lombard L; Baygani S; Raskin J; Krege JH; Loo LS; Komori M; Tobin J
    Cephalalgia; 2020 Jan; 40(1):19-27. PubMed ID: 31744319
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Preclinical pharmacological profile of the selective 5-HT1F receptor agonist lasmiditan. A comment.
    Maggioni F; Pini LA; Zanchin G
    Cephalalgia; 2011 Jul; 31(9):1061. PubMed ID: 21511951
    [No Abstract]   [Full Text] [Related]  

  • 56. Migraine history and response to lasmiditan across racial and ethnic groups.
    Charleston L; Savage-Edwards B; Bragg SM; Baygani SK; Dennehy EB
    Curr Med Res Opin; 2022 May; 38(5):721-730. PubMed ID: 35350937
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Serotonin receptor agonists in the acute treatment of migraine: a review on their therapeutic potential.
    Negro A; Koverech A; Martelletti P
    J Pain Res; 2018; 11():515-526. PubMed ID: 29563831
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Tolerability and Safety of Lasmiditan Treatment in Elderly Patients With Migraine: Post Hoc Analyses From Randomized Studies.
    Martin VT; Ahmed Z; Hochstetler HM; Baygani SK; Dong Y; Hauck PM; Khanna R
    Clin Ther; 2021 Jun; 43(6):1066-1078. PubMed ID: 34366152
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The need for new acutely acting antimigraine drugs: moving safely outside acute medication overuse.
    van Hoogstraten WS; MaassenVanDenBrink A
    J Headache Pain; 2019 May; 20(1):54. PubMed ID: 31096904
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Efficacy of Lasmiditan Across Patient and Migraine Characteristics in Japanese Patients with Migraine: A Secondary Analysis of the MONONOFU Trial.
    Takeshima T; Komori M; Tanji Y; Ozeki A; Tatsuoka Y
    Adv Ther; 2022 Nov; 39(11):5274-5288. PubMed ID: 36138260
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.